{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T11:04:49Z","timestamp":1794567889434,"version":"4.9.1"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,2,8]],"date-time":"2013-02-08T00:00:00Z","timestamp":1360281600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1471-244x-13-50","type":"journal-article","created":{"date-parts":[[2013,2,8]],"date-time":"2013-02-08T08:15:03Z","timestamp":1360311303000},"source":"Crossref","is-referenced-by-count":407,"title":["The nature of relapse in schizophrenia"],"prefix":"10.1186","volume":"13","author":[{"given":"Robin","family":"Emsley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonginkosi","family":"Chiliza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Asmal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian H","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,8]]},"reference":[{"key":"1241_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","volume":"56","author":"D Robinson","year":"1999","unstructured":"Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al: Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999, 56: 241-247. 10.1001\/archpsyc.56.3.241.","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl 14","key":"1241_CR2","first-page":"27","volume":"68","author":"JM Kane","year":"2007","unstructured":"Kane JM: Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry. 2007, 68 (Suppl 14): 27-30.","journal-title":"J Clin Psychiatry"},{"key":"1241_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/schbul\/23.1.3","volume":"23","author":"RJ Wyatt","year":"1997","unstructured":"Wyatt RJ: Research in schizophrenia and the discontinuation of antipsychotic medications. Schizophr Bull. 1997, 23: 3-9. 10.1093\/schbul\/23.1.3.","journal-title":"Schizophr Bull"},{"key":"1241_CR4","doi-asserted-by":"publisher","first-page":"13S","DOI":"10.1016\/0893-133X(95)00200-W","volume":"14","author":"JA Lieberman","year":"1996","unstructured":"Lieberman JA, Alvir JM, Koreen A, Geisler S, Chakos M, Sheitman B, et al: Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology. 1996, 14: 13S-21S. 10.1016\/0893-133X(95)00200-W.","journal-title":"Neuropsychopharmacology"},{"key":"1241_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.schres.2012.05.007","volume":"139","author":"M Alvarez-Jimenez","year":"2012","unstructured":"Alvarez-Jimenez M, Priede A, Hetrick SE, Bendall S, Killackey E, Parker AG, et al: Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res. 2012, 139: 116-128. 10.1016\/j.schres.2012.05.007.","journal-title":"Schizophr Res"},{"key":"1241_CR6","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1034\/j.1600-0447.2002.02437.x","volume":"106","author":"EL Coldham","year":"2002","unstructured":"Coldham EL, Addington J, Addington D: Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand. 2002, 106: 286-290. 10.1034\/j.1600-0447.2002.02437.x.","journal-title":"Acta Psychiatr Scand"},{"key":"1241_CR7","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1176\/appi.ajp.2011.10081224","volume":"168","author":"J Tiihonen","year":"2011","unstructured":"Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P: A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011, 168: 603-609. 10.1176\/appi.ajp.2011.10081224.","journal-title":"Am J Psychiatry"},{"key":"1241_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/01.pra.0000336756.65308.83","volume":"14","author":"BJ Miller","year":"2008","unstructured":"Miller BJ: A review of second-generation antipsychotic discontinuation in first-episode psychosis. J Psychiatr Pract. 2008, 14: 289-300. 10.1097\/01.pra.0000336756.65308.83.","journal-title":"J Psychiatr Pract"},{"key":"1241_CR9","doi-asserted-by":"publisher","first-page":"45","DOI":"10.9758\/cpn.2011.9.2.45","volume":"9","author":"BJ Miller","year":"2011","unstructured":"Miller BJ, Bodenheimer C, Crittenden K: Second-Generation Antipsychotic Discontinuation in First Episode Psychosis: An Updated Review. Clin Psychopharmacol Neurosci. 2011, 9: 45-53.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"1241_CR10","volume-title":"In J Clin Psychiatry","author":"R Emsley","year":"2012","unstructured":"Emsley R, Oosthuizen PP, Koen L, Niehaus DJ, Martinez L: Symptom Recurrence Following Intermittent Treatment in First Episode Schizophrenia Successfully Treated for Two Years. In J Clin Psychiatry. 2012, In press"},{"issue":"1","key":"1241_CR11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.schres.2012.02.030","volume":"138","author":"R Emsley","year":"2012","unstructured":"Emsley R, Nuamah I, Hough D, Gopal S: Treatment response after relapse in a placebo controlled maintenance trial in schizophrenia. Schizophr Res. 2012, 138 (1): 29-34. 10.1016\/j.schres.2012.02.030. Epub 2012 Mar 23","journal-title":"Schizophr Res"},{"issue":"1","key":"1241_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/JCP.0b013e31827bfcc1","volume":"33","author":"R Emsley","year":"2013","unstructured":"Emsley R, Oosthuizen PP, Koen L, Niehaus DJ, Martinez L: Comparison of Treatment Response in Second Episode Versus First Episode Schizophrenia. J Clin Psychopharmaco. 2013, 33 (1): 80-83. 10.1097\/JCP.0b013e31827bfcc1.","journal-title":"J Clin Psychopharmaco"},{"key":"1241_CR13","first-page":"127","volume-title":"Schizophrenia","author":"HJ Moller","year":"1995","unstructured":"Moller HJ, von Ziersen D, et al: Course and outcome of schizophrenia. Schizophrenia. 1995, Oxford: Blackwell, 127-"},{"key":"1241_CR14","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890427583","volume-title":"Tardive dyskinesia: A task force report of the American Psychiatric Association","author":"JM Kane","year":"1992","unstructured":"Kane JM, Jeste DV, Barnes TR: Tardive dyskinesia: A task force report of the American Psychiatric Association. 1992, Washington, D.C: American Psychiatric Association, Ref Type: Report"},{"key":"1241_CR15","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/archpsyc.1995.03950150032005","volume":"52","author":"HY Meltzer","year":"1995","unstructured":"Meltzer HY: Neuroleptic withdrawal in schizophrenic patients. An idea whose time has come. Arch Gen Psychiatry. 1995, 52: 200-202.","journal-title":"An idea whose time has come. Arch Gen Psychiatry"},{"issue":"Suppl 1","key":"1241_CR16","first-page":"20","volume":"68","author":"JW Newcomer","year":"2007","unstructured":"Newcomer JW: Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007, 68 (Suppl 1): 20-27.","journal-title":"J Clin Psychiatry"},{"key":"1241_CR17","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1592\/phco.29.1.64","volume":"29","author":"JR Bostwick","year":"2009","unstructured":"Bostwick JR, Guthrie SK, Ellingrod VL: Antipsychotic-induced hyperprolactinemia. Pharmacotherapy. 2009, 29: 64-73. 10.1592\/phco.29.1.64.","journal-title":"Pharmacotherapy"},{"key":"1241_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1097\/YCO.0b013e3282f53132","volume":"21","author":"CU Correll","year":"2008","unstructured":"Correll CU, Schenk EM: Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008, 21: 151-156. 10.1097\/YCO.0b013e3282f53132.","journal-title":"Curr Opin Psychiatry"},{"key":"1241_CR19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4088\/JCP.v69n0114","volume":"69","author":"DO Perkins","year":"2008","unstructured":"Perkins DO, Gu H, Weiden PJ, McEvoy JP, Hamer RM, Lieberman JA: Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry. 2008, 69: 106-113. 10.4088\/JCP.v69n0114.","journal-title":"J Clin Psychiatry"},{"key":"1241_CR20","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/archpsyc.1995.03950150005001","volume":"52","author":"PL Gilbert","year":"1995","unstructured":"Gilbert PL, Harris MJ, McAdams LA, Jeste DV: Neuroleptic withdrawal in schizophrenic patients. A review of the literature. Arch Gen Psychiatry. 1995, 52: 173-188. 10.1001\/archpsyc.1995.03950150005001.","journal-title":"Arch Gen Psychiatry"},{"key":"1241_CR21","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1176\/appi.ajp.158.11.1835","volume":"158","author":"M Gitlin","year":"2001","unstructured":"Gitlin M, Nuechterlein K, Subotnik KL, Ventura J, Mintz J, Fogelson DL, et al: Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia. Am J Psychiatry. 2001, 158: 1835-1842. 10.1176\/appi.ajp.158.11.1835.","journal-title":"Am J Psychiatry"},{"key":"1241_CR22","doi-asserted-by":"publisher","first-page":"c4024","DOI":"10.1136\/bmj.c4024","volume":"341","author":"EY Chen","year":"2010","unstructured":"Chen EY, Hui CL, Lam MM, Chiu CP, Law CW, Chung DW, et al: Maintenance treatment with quetiapine versus discontinuation after one year of treatment in patients with remitted first episode psychosis: randomised controlled trial. BMJ. 2010, 341: c4024-10.1136\/bmj.c4024.","journal-title":"BMJ"},{"key":"1241_CR23","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3109\/13651501.2010.534801","volume":"15","author":"G Boonstra","year":"2011","unstructured":"Boonstra G, Burger H, Grobbee DE, Kahn RS: Antipsychotic prophylaxis is needed after remission from a first psychotic episode in schizophrenia patients: results from an aborted randomised trial. Int J Psychiatry Clin Pract. 2011, 15: 128-134. 10.3109\/13651501.2010.534801.","journal-title":"Int J Psychiatry Clin Pract"},{"key":"1241_CR24","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1001\/archpsyc.1982.04290010048009","volume":"39","author":"JM Kane","year":"1982","unstructured":"Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J: Fluphenazine vs placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry. 1982, 39: 70-73. 10.1001\/archpsyc.1982.04290010048009.","journal-title":"Arch Gen Psychiatry"},{"key":"1241_CR25","doi-asserted-by":"publisher","first-page":"654","DOI":"10.4088\/JCP.v68n0502","volume":"68","author":"L Wunderink","year":"2007","unstructured":"Wunderink L, Nienhuis FJ, Sytema S, Slooff CJ, Knegtering R, Wiersma D: Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. J Clin Psychiatry. 2007, 68: 654-661. 10.4088\/JCP.v68n0502.","journal-title":"J Clin Psychiatry"},{"key":"1241_CR26","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1192\/bjp.148.2.120","volume":"148","author":"TJ Crow","year":"1986","unstructured":"Crow TJ, MacMillan JF, Johnson AL, Johnstone EC: A randomised controlled trial of prophylactic neuroleptic treatment. In Br J Psychiatry. 1986, 148: 120-127. 10.1192\/bjp.148.2.120.","journal-title":"In Br J Psychiatry"},{"key":"1241_CR27","doi-asserted-by":"publisher","first-page":"205","DOI":"10.4088\/JCP.09m05459yel","volume":"72","author":"W Gaebel","year":"2011","unstructured":"Gaebel W, Riesbeck M, Wolwer W, Klimke A, Eickhoff M, Von WM, et al: Relapse prevention in first-episode schizophrenia\u2013maintenance vs intermittent drug treatment with prodrome-based early intervention: results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry. 2011, 72: 205-218. 10.4088\/JCP.09m05459yel.","journal-title":"J Clin Psychiatry"},{"key":"1241_CR28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.schres.2011.11.021","volume":"134","author":"H Takeuchi","year":"2012","unstructured":"Takeuchi H, Suzuki T, Uchida H, Watanabe K, Mimura M: Antipsychotic treatment for schizophrenia in the maintenance phase: a systematic review of the guidelines and algorithms. Schizophr Res. 2012, 134: 219-225. 10.1016\/j.schres.2011.11.021.","journal-title":"Schizophr Res"},{"key":"1241_CR29","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1017\/S1461145704004924","volume":"8","author":"O Gefvert","year":"2005","unstructured":"Gefvert O, Eriksson B, Persson P, Helldin L, Bjorner A, Mannaert E, et al: Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol. 2005, 8: 27-36. 10.1017\/S1461145704004924.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1241_CR30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1600-0447.2006.00787.x","volume":"114","author":"J Moncrieff","year":"2006","unstructured":"Moncrieff J: Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr Scand. 2006, 114: 3-13.","journal-title":"Acta Psychiatr Scand"},{"key":"1241_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1176\/ajp.137.8.992-a","volume":"137","author":"G Chouinard","year":"1980","unstructured":"Chouinard G, Jones BD: Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. Am J Psychiatry. 1980, 137: 16-21.","journal-title":"Am J Psychiatry"},{"key":"1241_CR32","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1017\/S0033291700024247","volume":"19","author":"M Birchwood","year":"1989","unstructured":"Birchwood M, Smith J, MacMillan F, Hogg B, Prasad R, Harvey C, et al: Predicting relapse in schizophrenia: the development and implementation of an early signs monitoring system using patients and families as observers, a preliminary investigation. Psychol Med. 1989, 19: 649-656. 10.1017\/S0033291700024247.","journal-title":"Psychol Med"},{"key":"1241_CR33","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/schbul\/22.2.353","volume":"22","author":"AR Yung","year":"1996","unstructured":"Yung AR, McGorry PD: The prodromal phase of first-episode psychosis: past and current conceptualizations. Schizophr Bull. 1996, 22: 353-370. 10.1093\/schbul\/22.2.353.","journal-title":"Schizophr Bull"},{"key":"1241_CR34","first-page":"553","volume":"21","author":"J Bustillo","year":"1995","unstructured":"Bustillo J: Buchanan RW. Carpenter WT Jr: Prodromal symptoms vs. early warning signs and clinical action in schizophrenia. Schizophr Bull. 1995, 21: 553-559.","journal-title":"Carpenter WT Jr: Prodromal symptoms vs. early warning signs and clinical action in schizophrenia. Schizophr Bull"},{"key":"1241_CR35","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1093\/schbul\/21.4.527","volume":"21","author":"RM Norman","year":"1995","unstructured":"Norman RM, Malla AK: Prodromal symptoms of relapse in schizophrenia: a review. Schizophr Bull. 1995, 21: 527-539. 10.1093\/schbul\/21.4.527.","journal-title":"Schizophr Bull"},{"key":"1241_CR36","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.schres.2007.06.016","volume":"95","author":"W Gaebel","year":"2007","unstructured":"Gaebel W, Riesbeck M: Revisiting the relapse predictive validity of prodromal symptoms in schizophrenia. Schizophr Res. 2007, 95: 19-29. 10.1016\/j.schres.2007.06.016.","journal-title":"Schizophr Res"},{"key":"1241_CR37","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1192\/S0007125000292416","volume":"21","author":"W Gaebel","year":"1993","unstructured":"Gaebel W, Frick U, Kopcke W, Linden M, Muller P, Muller-Spahn F, et al: Early neuroleptic intervention in schizophrenia: are prodromal symptoms valid predictors of relapse?. Br J Psychiatry Suppl. 1993, 21: 8-12.","journal-title":"Br J Psychiatry Suppl"},{"key":"1241_CR38","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1176\/ajp.137.7.801","volume":"137","author":"MI Herz","year":"1980","unstructured":"Herz MI, Melville C: Relapse in schizophrenia. Am J Psychiatry. 1980, 137: 801-805.","journal-title":"Am J Psychiatry"},{"key":"1241_CR39","first-page":"753","volume":"47","author":"Y Henmi","year":"1993","unstructured":"Henmi Y: Prodromal symptoms of relapse in schizophrenic outpatients: retrospective and prospective study. Jpn J Psychiatry Neurol. 1993, 47: 753-775.","journal-title":"Jpn J Psychiatry Neurol"},{"key":"1241_CR40","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF00795207","volume":"26","author":"N Tarrier","year":"1991","unstructured":"Tarrier N, Barrowclough C, Bamrah JS: Prodromal signs of relapse in schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 1991, 26: 157-161.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"1241_CR41","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.schres.2005.07.019","volume":"80","author":"JF Gleeson","year":"2005","unstructured":"Gleeson JF, Rawlings D, Jackson HJ, McGorry PD: Early warning signs of relapse following a first episode of psychosis. Schizophr Res. 2005, 80: 107-111. 10.1016\/j.schres.2005.07.019.","journal-title":"Schizophr Res"},{"key":"1241_CR42","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0272-7358(01)00105-2","volume":"21","author":"M Birchwood","year":"2001","unstructured":"Birchwood M, Spencer E: Early intervention in psychotic relapse. Clin Psychol Rev. 2001, 21: 1211-1226. 10.1016\/S0272-7358(01)00105-2.","journal-title":"Clin Psychol Rev"},{"key":"1241_CR43","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/JCP.0b013e318167269d","volume":"28","author":"R Emsley","year":"2008","unstructured":"Emsley R, Medori R, Koen L, Oosthuizen PP, Niehaus DJ, Rabinowitz J: Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study. J Clin Psychopharmacol. 2008, 28: 210-213. 10.1097\/JCP.0b013e318167269d.","journal-title":"J Clin Psychopharmacol"},{"key":"1241_CR44","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/schbul\/17.2.325","volume":"17","author":"RJ Wyatt","year":"1991","unstructured":"Wyatt RJ: Neuroleptics and the natural course of schizophrenia. Schizophr Bull. 1991, 17: 325-351. 10.1093\/schbul\/17.2.325.","journal-title":"Schizophr Bull"},{"key":"1241_CR45","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1001\/archpsyc.1993.01820170047006","volume":"50","author":"JA Lieberman","year":"1993","unstructured":"Lieberman JA, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, et al: Time course and biologic correlates of treatment response in first-episode schizophrenia. Arch Gen Psychiatry. 1993, 50: 369-376. 10.1001\/archpsyc.1993.01820170047006.","journal-title":"Arch Gen Psychiatry"},{"key":"1241_CR46","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1001\/archpsyc.62.9.975","volume":"62","author":"M Marshall","year":"2005","unstructured":"Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T: Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry. 2005, 62: 975-983. 10.1001\/archpsyc.62.9.975.","journal-title":"Arch Gen Psychiatry"},{"key":"1241_CR47","first-page":"739","volume":"48","author":"JP McEvoy","year":"1991","unstructured":"McEvoy JP, Hogarty GE, Steingard S: Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry. 1991, 48: 739-745.","journal-title":"A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry"},{"key":"1241_CR48","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1192\/bjp.146.5.474","volume":"146","author":"DA Curson","year":"1985","unstructured":"Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC: Long-term depot maintenance of chronic schizophrenic out-patients: the seven year follow-up of the Medical Research Council fluphenazine\/placebo trial. III. Relapse postponement or relapse prevention? The implications for long-term outcome. Br J Psychiatry. 1985, 146: 474-480. 10.1192\/bjp.146.5.474.","journal-title":"Br J Psychiatry"},{"key":"1241_CR49","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/0006-3223(92)90124-I","volume":"31","author":"D Glovinsky","year":"1992","unstructured":"Glovinsky D, Kirch DG, Wyatt RJ: Early antipsychotic response to resumption of neuroleptics in drug-free chronic schizophrenic patients. Biol Psychiatry. 1992, 31: 968-970. 10.1016\/0006-3223(92)90124-I.","journal-title":"Biol Psychiatry"},{"key":"1241_CR50","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/S0006-3223(99)00227-9","volume":"46","author":"RJ Wyatt","year":"1999","unstructured":"Wyatt RJ, Henter ID, Bartko JJ: The long-term effects of placebo in patients with chronic schizophrenia. Biol Psychiatry. 1999, 46: 1092-1105. 10.1016\/S0006-3223(99)00227-9.","journal-title":"Biol Psychiatry"},{"key":"1241_CR51","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.biopsych.2010.01.012","volume":"68","author":"SZ Levine","year":"2010","unstructured":"Levine SZ, Leucht S: Elaboration on the early-onset hypothesis of antipsychotic drug action: treatment response trajectories. Biol Psychiatry. 2010, 68: 86-92. 10.1016\/j.biopsych.2010.01.012.","journal-title":"Biol Psychiatry"},{"key":"1241_CR52","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/schbul\/sbl032","volume":"32","author":"TH McGlashan","year":"2006","unstructured":"McGlashan TH: Is active psychosis neurotoxic?. Schizophr Bull. 2006, 32: 609-613.","journal-title":"Schizophr Bull"},{"key":"1241_CR53","volume-title":"Schizophr Bull","author":"RB Zipursky","year":"2012","unstructured":"Zipursky RB, Reilly JL, Murray RM: The myth of schizophrenia as a progressive brain disease. Schizophr Bull. 2012, Epub ahead of print"},{"key":"1241_CR54","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1093\/oxfordjournals.schbul.a033315","volume":"24","author":"D Wiersma","year":"1998","unstructured":"Wiersma D, Nienhuis FJ, Slooff CJ, Giel R: Natural course of schizophrenic disorders: a 15-year followup of a Dutch incidence cohort. Schizophr Bull. 1998, 24: 75-85. 10.1093\/oxfordjournals.schbul.a033315.","journal-title":"Schizophr Bull"},{"key":"1241_CR55","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.pnpbp.2003.09.004","volume":"27","author":"S Kapur","year":"2003","unstructured":"Kapur S, Mamo D: Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry. 2003, 27: 1081-1090. 10.1016\/j.pnpbp.2003.09.004.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1241_CR56","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/schbul\/sbp006","volume":"35","author":"OD Howes","year":"2009","unstructured":"Howes OD, Kapur S: The dopamine hypothesis of schizophrenia: version III\u2013the final common pathway. Schizophr Bull. 2009, 35: 549-562. 10.1093\/schbul\/sbp006.","journal-title":"Schizophr Bull"},{"issue":"8","key":"1241_CR57","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1001\/archgenpsychiatry.2012.169","volume":"69","author":"OD Howes","year":"2012","unstructured":"Howes OD, Kambeitz J, Kim E, Stahl D, Slifstein M, Abi-Dargham A, et al: The Nature of Dopamine Dysfunction in Schizophrenia and What This Means for Treatment: Meta-analysis of Imaging Studies. Arch Gen Psychiatry. 2012, 69 (8): 776-786. 10.1001\/archgenpsychiatry.2012.169.","journal-title":"Arch Gen Psychiatry"},{"key":"1241_CR58","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1176\/appi.ajp.160.1.13","volume":"160","author":"S Kapur","year":"2003","unstructured":"Kapur S: Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry. 2003, 160: 13-23. 10.1176\/appi.ajp.160.1.13.","journal-title":"Am J Psychiatry"},{"key":"1241_CR59","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1001\/archpsyc.60.12.1228","volume":"60","author":"O Agid","year":"2003","unstructured":"Agid O, Kapur S, Arenovich T, Zipursky RB: Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry. 2003, 60: 1228-1235. 10.1001\/archpsyc.60.12.1228.","journal-title":"Arch Gen Psychiatry"},{"key":"1241_CR60","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1016\/j.biopsych.2005.02.023","volume":"57","author":"S Leucht","year":"2005","unstructured":"Leucht S, Busch R, Hamann J, Kissling W, Kane JM: Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry. 2005, 57: 1543-1549. 10.1016\/j.biopsych.2005.02.023.","journal-title":"Biol Psychiatry"},{"key":"1241_CR61","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1176\/ajp.2006.163.4.743","volume":"163","author":"R Emsley","year":"2006","unstructured":"Emsley R, Rabinowitz J, Medori R: Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry. 2006, 163: 743-745. 10.1176\/appi.ajp.163.4.743.","journal-title":"Am J Psychiatry"},{"key":"1241_CR62","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.nurx.2005.12.003","volume":"3","author":"S Kapur","year":"2006","unstructured":"Kapur S, Agid O, Mizrahi R, Li M: How antipsychotics work-from receptors to reality. NeuroRx. 2006, 3: 10-21. 10.1016\/j.nurx.2005.12.003.","journal-title":"NeuroRx"},{"key":"1241_CR63","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3389\/fphar.2012.00195","volume":"3","author":"TL Schwartz","year":"2012","unstructured":"Schwartz TL, Sachdeva S, Stahl SM: Glutamate neurocircuitry: theoretical underpinnings in schizophrenia. Front Pharmacol. 2012, 3: 195-","journal-title":"Front Pharmacol"},{"key":"1241_CR64","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1177\/0269881111431622","volume":"26","author":"BE Leonard","year":"2012","unstructured":"Leonard BE, Schwarz M, Myint AM: The metabolic syndrome in schizophrenia: is inflammation a contributing cause?. J Psychopharmacol. 2012, 26: 33-41. 10.1177\/0269881111431622.","journal-title":"J Psychopharmacol"},{"key":"1241_CR65","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.bbi.2006.02.002","volume":"20","author":"L Drzyzga","year":"2006","unstructured":"Drzyzga L, Obuchowicz E, Marcinowska A, Herman ZS: Cytokines in schizophrenia and the effects of antipsychotic drugs. Brain Behav Immun. 2006, 20: 532-545. 10.1016\/j.bbi.2006.02.002.","journal-title":"Brain Behav Immun"},{"key":"1241_CR66","doi-asserted-by":"crossref","unstructured":"Moller M, Du Preez JL, Viljoen FP, Berk M, Emsley R, Harvey BH: Social isolation rearing induces mitochondrial, immunological, neurochemical and behavioural deficits in rats, and is reversed by clozapine or N-acetyl cysteine. Brain Behavior and Immunity. 10.1016\/j.bbi.2012.12.011. Epub ahead of print","DOI":"10.1016\/j.bbi.2012.12.011"},{"key":"1241_CR67","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1176\/ajp.152.9.1291","volume":"152","author":"CG McAllister","year":"1995","unstructured":"McAllister CG, van Kammen DP, Rehn TJ, Miller AL, Gurklis J, Kelley ME, et al: Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry. 1995, 152: 1291-1297.","journal-title":"Am J Psychiatry"},{"key":"1241_CR68","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","volume":"70","author":"BJ Miller","year":"2011","unstructured":"Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B: Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry. 2011, 70: 663-671. 10.1016\/j.biopsych.2011.04.013.","journal-title":"Biol Psychiatry"},{"key":"1241_CR69","volume-title":"Biol Psychiatry","author":"BJ Miller","year":"2012","unstructured":"Miller BJ, Gassama B, Sebastian D, Buckley P, Mellor A: Meta-Analysis of Lymphocytes in Schizophrenia: Clinical Status and Antipsychotic Effects. Biol Psychiatry. 2012, doi:10.1016\/j.biopsych.2012.09.007. doi:pii: S0006-3223(12):00779-2."},{"key":"1241_CR70","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/S0006-3223(03)00528-6","volume":"54","author":"BH Harvey","year":"2003","unstructured":"Harvey BH, McEwen BS, Stein DJ: Neurobiology of antidepressant withdrawal: implications for the longitudinal outcome of depression. Biol Psychiatry. 2003, 54: 1105-1117. 10.1016\/S0006-3223(03)00528-6.","journal-title":"Biol Psychiatry"},{"key":"1241_CR71","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/S0301-0082(99)00064-7","volume":"61","author":"OA Andreassen","year":"2000","unstructured":"Andreassen OA, Jorgensen HA: Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats, implications for tardive dyskinesia. Prog Neurobiol. 2000, 61: 525-531. 10.1016\/S0301-0082(99)00064-7.","journal-title":"Prog Neurobiol"},{"key":"1241_CR72","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/00008877-200105000-00006","volume":"12","author":"PS Naidu","year":"2001","unstructured":"Naidu PS, Kulkarni SK: Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide. Behav Pharmacol. 2001, 12: 209-216. 10.1097\/00008877-200105000-00006.","journal-title":"Behav Pharmacol"},{"key":"1241_CR73","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/00008877-200305000-00010","volume":"14","author":"A Nel","year":"2003","unstructured":"Nel A, Harvey BH: Haloperidol-induced dyskinesia is associated with striatal NO synthase suppression: reversal with olanzapine. Behav Pharmacol. 2003, 14: 251-255. 10.1097\/00008877-200305000-00010.","journal-title":"Behav Pharmacol"},{"key":"1241_CR74","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s11064-007-9466-y","volume":"33","author":"BH Harvey","year":"2008","unstructured":"Harvey BH, Joubert C, du Preez JL, Berk M: Effect of chronic N-acetyl cysteine administration on oxidative status in the presence and absence of induced oxidative stress in rat striatum. Neurochem Res. 2008, 33: 508-517. 10.1007\/s11064-007-9466-y.","journal-title":"Neurochem Res"},{"key":"1241_CR75","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0166-4328(00)00156-X","volume":"111","author":"BH Harvey","year":"2000","unstructured":"Harvey BH, Bester A: Withdrawal-associated changes in peripheral nitrogen oxides and striatal cyclic GMP after chronic haloperidol treatment. Behav Brain Res. 2000, 111: 203-211. 10.1016\/S0166-4328(00)00156-X.","journal-title":"Behav Brain Res"},{"key":"1241_CR76","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.biopsych.2008.03.004","volume":"64","author":"M Berk","year":"2008","unstructured":"Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, et al: N-acetyl cysteine as a glutathione precursor for schizophrenia\u2013a double-blind, randomized, placebo-controlled trial. Biol Psychiatry. 2008, 64: 361-368. 10.1016\/j.biopsych.2008.03.004.","journal-title":"Biol Psychiatry"},{"key":"1241_CR77","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1176\/ajp.155.4.565","volume":"155","author":"PN van Harten","year":"1998","unstructured":"van Harten PN, Hoek HW, Matroos GE, Koeter M, Kahn RS: Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curacao Extrapyramidal Syndromes Study III. Am J Psychiatry. 1998, 155: 565-567.","journal-title":"Am J Psychiatry"},{"key":"1241_CR78","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1523\/JNEUROSCI.5416-06.2007","volume":"27","author":"AN Samaha","year":"2007","unstructured":"Samaha AN, Seeman P, Stewart J, Rajabi H, Kapur S: \"Breakthrough\" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci. 2007, 27: 2979-2986. 10.1523\/JNEUROSCI.5416-06.2007.","journal-title":"J Neurosci"},{"key":"1241_CR79","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","volume":"379","author":"S Leucht","year":"2012","unstructured":"Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al: Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012, 379: 2063-2071. 10.1016\/S0140-6736(12)60239-6.","journal-title":"Lancet"},{"key":"1241_CR80","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.biopsych.2007.08.018","volume":"63","author":"GT Konopaske","year":"2008","unstructured":"Konopaske GT, Dorph-Petersen KA, Sweet RA, Pierri JN, Zhang W, Sampson AR, et al: Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biol Psychiatry. 2008, 63: 759-765. 10.1016\/j.biopsych.2007.08.018.","journal-title":"Biol Psychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-13-50.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-244X-13-50\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-244X-13-50","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T16:23:01Z","timestamp":1745943781000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/1471-244X-13-50"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,8]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["1241"],"URL":"https:\/\/doi.org\/10.1186\/1471-244x-13-50","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,8]]},"article-number":"50"}}